Status and phase
Conditions
Treatments
About
This is a clinical trial in relapsing-remitting Multiple Sclerosis to determine if Topamax added to Avonex has a neuroprotective effect as measured by the brain parenchymal fraction ( a measure of brain shrinkage) and by clinical assessment scores to evaluate disease progression.
Full description
The protocol requires all participants to be treated with Avonex and in addition patients will be blindly assigned to either a group who receive Topamax or a placebo control. Repeated neurological and clinical examinations are performed with laboratory tests to determine any possible adverse drug effects. The scaled neurologic examinations (EDSS and MSFC) and brain MRI's are done at regular intervals to evaluate possible treatment effects.
Sex
Ages
Volunteers
Inclusion criteria
Relapsing-remitting multiple sclerosis
Exclusion criteria
Secondary progressive multiple sclerosis Contraindication to MRI Systemic disease Pregnancy -
Primary purpose
Allocation
Interventional model
Masking
Loading...
Central trial contact
Jeffrey I Greenstein, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal